At 100 years of activity, Biofarm Bucharest inaugurates one of the most modern drug factories in Romania and launches Biofen Extra

Must Read

Romania recorded the largest increase in construction works in 2023

Bucuresti, 10 February, 2024 - # RBJ - In December 2023, compared with November 2023, seasonally adjusted production in...

SeedBlink launches ESOP Design program to help Romanian entrepreneurs reward their employees through shares

The program is adapted to the specific legal and tax environment in Romania. It is made in collaboration with...

Algeria is taking the place of Russia, slowly but surely, in the gas supply of Central Europe

Bucharest, February 17, 2024 - # RBJ (photo: Algerian gas pipelines to Italy and Spain) - Last week, the...

Catalin Vicol, CEO Biofarm Bucharest

By rbj
Biofarm, one of the most important drug manufacturers in Romania, reports positive developments for the preliminary results of 2021: turnover of 239 million lei and a net profit of 60 million lei, up 11% compared to 2020. In addition, Biofarm reported EBITDA of 82 million lei, up 10% compared to 2020.
“Innovation, the driving force behind Biofarm’s mission, is strongly reflected in the figures for 2021, a year marked by significant achievements in all areas. The main events that defined Biofarm in 2021 were: the celebration of 100 years of uninterrupted activity, the inauguration of one of the most modern drug factories in Romania and the launch of Biofen Extra, through which we activated one of the most important CHC categories in terms of business potential,” said Cătălin Vicol, General Manager of Biofarm.
In terms of sell-out (sales from pharmacies to patients), Biofarm finished last year on the second position in terms of volume, respectively on the fourth position in terms of value in the category of CHC (Consumer Health Care). The launch of Biofen Extra consolidates Biofarm’s position in the top companies in the CHC category by activating one of the most important CHC categories in Romania – pain management. Biofen Extra, an OTC (Over-the-Counter) drug indicated in the treatment of severe pain, became a value leader in the ibuprofen and paracetamol combination segment within the first 8 months of its launch.
At the end of 2021, in the CHC category, Biofarm is the volume leader in the reference markets of nine brands in the portfolio: Colebil, Triferment, Bixtonim, Sennalax, Carmol, Nervocalmin, Carbocit, Extravalerianic and Devaricid.
Constant investments to increase brand capital, especially for the main brands in Biofarm’s portfolio, were also an important pillar in 2021. Over the past year, the process of revitalizing the visual identity for 9 other brands in Biofarm’s portfolio was completed. Consistent resources have also been allocated to launch new 360-degree communication campaigns to increase notoriety and test rate for portfolio-focused focus brands.
Biofarm’s portfolio covers the most important therapeutic areas in the Consumer Healthcare division – digestive & metabolic, respiratory & ORL, cardiovascular & circulatory, nervous system, multivitamins, with over 20 representative brands.
Biofarm continues to invest in the future and make a significant contribution to the long-term development of the Romanian pharmaceutical industry.
The state-of-the-art manufacturing equipment/systems in the new production facility allow continuous process monitoring, thus ensuring the production of high-quality medicines that meet the most stringent requirements of European legislation.
With a usable area of over 10,000 square meters and an annual production flow of over 30 million commercial units of tablets and capsules and more than 10 million liquid products, the new Biofarm plant is in line with the company’s strategic objectives: developing the portfolio through line extensions or new product launches and expanding to external markets.
Biofarm® is one of the first Romanian producers of medicines and food supplements. For 100 years Biofarm® has been with the specialists in Romania in the race to find the best solutions for maintaining human health. Today, Biofarm® is one of the top 10 manufacturers on the Romanian pharmaceutical market, a dynamic and highly competitive market. Biofarm® has a competitive product portfolio covering 65 therapeutic areas and continuously invests in media, commercial and marketing campaigns to promote its own products.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -
Latest News

Romania recorded the largest increase in construction works in 2023

Bucuresti, 10 February, 2024 - # RBJ - In December 2023, compared with November 2023, seasonally adjusted production in...

SeedBlink launches ESOP Design program to help Romanian entrepreneurs reward their employees through shares

The program is adapted to the specific legal and tax environment in Romania. It is made in collaboration with Mavers Tax Advisory and Andronic...

Algeria is taking the place of Russia, slowly but surely, in the gas supply of Central Europe

Bucharest, February 17, 2024 - # RBJ (photo: Algerian gas pipelines to Italy and Spain) - Last week, the German Vice-Chancellor and Minister of...

Romania-Italy: action plan that will strengthen the relations between the two states to a higher level

Rome, February 15, 2024 - # RBJ (Source: Agerpres) - Romania and Italy are entering a new stage of development of their consolidated strategic...

The Economist Impact Events presents the fourth edition of the Romanian Business & Investment Roundtable Conference in Bucharest, between April 3-4, 2024

Bucharest, 15 February, 2024 - # RBJ - The Economist Impact Events and its official representative for South East Europe, Hazlis & Rivas, together...
- Advertisement -

More Articles Like This

- Advertisement -